1 |
Dinan TG, Cryan JF. Gut instincts: Microbiota as a key regulator of brain development, ageing and neurode-generation [J]. J Physiol, 2017, 595(2): 489-503.
|
2 |
Kumar A, Singh A, Ekavali. A review on Alzheimer′s disease pathophysiology and its management: an update [J]. Pharmacol Rep, 2015, 67(2): 195-203.
|
3 |
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease [J]. Nat Rev Neurosci, 2015, 16(6): 358-372.
|
4 |
Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? [J]. BMC Med, 2013, 11: 200.
|
5 |
Russo R, Cristiano C, Avagliano C, et al. Gut-brain axis: Role of lipids in the regulation of inflammation, pain and CNS diseases [J]. Curr Med Chem, 2017 Feb 16, Epub ahead of print.
|
6 |
Westfall S, Lomis N, Kahouli I, et al. Microbiome, probiotics and neurodegenerative disease: deciphering the gut brain axis [J]. Cell Mol Life Sci, 2017 Jun 22, Epub ahead of print.
|
7 |
Shoemark DK, Allen SJ. The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer′s disease [J]. J Alzheimer′s Dis, 2015, 43(3): 725-738.
|
8 |
Ostan R, Bucci L, Capri M, et al. Immunosenescence and immunogenetics of human longevity [J]. Neuroimmunomodulation, 2008, 15(4-6): 224-240.
|
9 |
Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age [J]. BMC Microbiol, 2009, 9: 123.
|
10 |
Claesson MJ, Cusack S, O′Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly [J]. Proc Natl Acad Sci USA, 2011, 108 Suppl 1: 4586-4591.
|
11 |
Kelly JR, Kennedy PJ, Cryan JF, et al. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders [J]. Front Cell Neurosci, 2015, 9: 392.
|
12 |
Zhang R, Miller RG, Gascon R, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS) [J]. J Neuroimmunol, 2009, 206(1-2): 121-124.
|
13 |
Jaeger LB, Dohgu S, Sultana R, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer′s disease [J]. Brain Behav Immun, 2009, 23(4): 507-517.
|
14 |
Lei YMK, Nair L, Alegre ML. The interplay between the intestinal microbiota and the immune system [J]. Clin Res Hepatol Gastroenterol, 2015, 39(1): 9-19.
|
15 |
Hasegawa M, Nonaka T, Masuda-Suzukake M. Prion-like mechanisms and potential therapeutic targets in neurodenerative disorders [J]. Pharmacol Ther, 2017, 172: 22-33.
|
16 |
Walker LC, Jucker M. Neurodegenerative diseases: Expanding the prion concept [J]. Annu Rev Neurosci, 2015, 38: 87-103.
|
17 |
Ano Y, Sakudo A, Nakayama H, et al. Uptake and dynamics of infectious prion protein in the intestine [J]. Protein Pept Lett, 2009, 16(3): 247-255.
|
18 |
Galloway S, Takechi R, Pallebage-Gamarallage MM, et al. Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small intestine [J]. Lipid Health Dis, 2009, 8: 46.
|
19 |
Schwartz K, Boles BR. Microbial amyloids--functions and interactions within the host [J]. Curr Opin Microbiol, 2013, 16(1): 93-99.
|
20 |
Pistollato F, Sumalla Cano S, Elio I, et al. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease [J]. Nutr Rev, 2016, 74(10): 624-634.
|
21 |
Zhao Y, Lukiw WJ. Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer′s disease(AD) [J]. J Nat sci, 2015, 1(7). pii: e138.
|
22 |
Bu XL, Yao XQ, Jiao SS, et al. A study on the association between infectious burden and Alzheimer′s disease [J]. Eur J Neurol, 2015, 22(12): 1519-1525.
|
23 |
Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance [J]. Mol Aspects Med, 2013, 34(1): 39-58.
|
24 |
Bjursell M, Admyre T, Goransson M, et al. Improved glu-cose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet [J]. Am J Physiol Endocrinol Metab, 2011, 300(1): E211-220.
|
25 |
Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? [J]. Curr Opin Clin Nutr Metab Care, 2010, 13(6): 715-721.
|
26 |
Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the shortchain fatty acid butyrate [J]. Int J Colorectal Dis, 2001, 16(4): 195-201.
|
27 |
Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism [J]. Nature, 2012, 489(7415): 242-249.
|
28 |
Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders:new insights into the gut microbiota [J]. Curr Opin Pharmacol, 2009, 9(6): 737-743.
|
29 |
Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice [J]. Proc Natl Acad Sci USA, 2006, 103(33): 12511-12516.
|
30 |
Ley RE, Backhed F, Tunbaugh P, et al. Obesity alters gut microbial ecology [J]. Proc Natl Acad Sci USA, 2005, 102(31): 11070-11075.
|
31 |
Walker AW, Parkhill J. Microbiology. Fighting obesity with bacteria [J]. Science, 2013, 341(6150): 109-170.
|
32 |
Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice[J]. Science, 2013, 341(6150): 1241214.
|
33 |
Cani PD, Osto M, Geurts L, et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity [J]. Gut Microbes, 2012, 3(4): 279-288.
|
34 |
Moreno-Navarrete JM, Sabater M, Ortega F, et al. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance [J]. PLoS One, 2012, 7(5): e37160.
|
35 |
de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation [J]. Am J Physiol Gastrointest Liver Physiol, 2010, 299(2): G440-448.
|
36 |
Zaccardi F, Webb DR, Yates T, et al. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective [J]. Postgrad Med J, 2016, 92(1084): 63-69.
|
37 |
Janson J, Laedtke T, Parisi JE, et al. Increased risk of type 2 diabetes in Alzheimer disease [J]. Diabetes, 2004, 53(2): 474-481.
|
38 |
Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer′s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline [J]. J Clin Invest, 2012, 122(4): 1316-1338.
|
39 |
Suzanne M, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer′s disease [J]. J Alzheimer′s Dis, 2005, 7(1): 45-61.
|
40 |
Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer′s disease–associated Aβ oligomers [J]. J Clin Invest, 2012, 122(4): 1339-1353.
|
41 |
Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes [J]. Curr Diab Rep, 2004, 4(4): 237-246.
|
42 |
Gasparini L, Gouras GK, Wang R, et al. Stimulation of betaamyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling [J]. J Neurosci, 2001, 21(8): 2561-2570.
|
43 |
Arab L, Sadeghi R, Walker D, et al. Consequences of aberrant insulin regulation in the brain: can treating diabetes be effective for Alzheimer′s disease [J]. Curr Neuropharmacol, 2011, 9(4): 693-705.
|
44 |
Lue L-F, Andrade C, Sabbagh M, et al. Is there inflammatory synergy in type II diabetes mellitus and Alzheimer′s Disease? [J]. Int J Alzheimer′s Dis, 2012, 2012: 918680.
|